Raymond James Financial Services Advisors, Inc. Ocugen, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	BUY	$0.36 - $0.57 $1,324 - $2,097	3,680 Added 19.12%	22,923 $13,000
Q3 2023 Oct 24, 2023	BUY	$0.4 - $0.62 $3,000 - $4,650	7,500 Added 63.87%	19,243 $7,000
Q2 2023 Jul 25, 2023	SELL	$0.45 - $0.88 $202 - $396	-450 Reduced 3.69%	11,743 $6,000
Q4 2022 Feb 08, 2023	SELL	$1.11 - $1.87 $2,540 - $4,280	-2,289 Reduced 15.81%	12,193 $15,000
Q3 2022 Oct 25, 2022	BUY	$1.75 - $3.1 $2,065 - $3,658	1,180 Added 8.87%	14,482 $26,000
Q2 2022 Aug 12, 2022	SELL	$1.83 - $3.45 $1,912 - $3,605	-1,045 Reduced 7.28%	13,302 $30,000
Q1 2022 May 11, 2022	BUY	$2.34 - $4.72 $33,571 - $67,717	14,347 New	14,347 $47,000

Others Institutions Holding OCGN

# of Institutions

124

Shares Held

78.3M

Call Options Held

535K

Put Options Held

523K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account